January 9, 2018 / 2:31 AM / 9 months ago

BRIEF-Kubota Pharmaceutical Holdings unit and SIRION Biotech set sights on gene delivery tools for ocular gene therapy

Jan 9 (Reuters) - Kubota Pharmaceutical Holdings Co Ltd

* Says co’s wholly owned unit Acucela Inc signed a two-year development agreement with gene delivery expert SIRION Biotech GmbH (SIRION) to establish optimized AAV vectors for clinical applications in ocular gene therapy

* Says Acucela bolsters its move into the fast growing gene therapy market to find a genetic cure for retinitis pigmentosa

* Key terms of the agreement include milestone payments to SIRION, with additional royalties to be paid on net sales from resulting products or therapies

Source text in Japanese: goo.gl/n8VbQu

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below